

Thalidomide-NH-C8-NH2 hydrochloride Biochemical

Thalidomide-NH-C8-NH2 hydrochloride

CATALOG #
AAA228443

PRODUCT SYNONYMS

Thalidomide-NH-C8-NH2 hydrochloride; Thalidomide-NH-C8-NH2 hydrochloride biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2446474-06-0
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
C-Peptide 2, rat, CAS 41594-08-5



Structure
C-Peptide 2, rat, CAS 41594-08-5

ADDITIONAL INFORMATION

Related Product Information for Thalidomide-NH-C8-NH2 hydrochloride biochemical	Thalidomide-NH-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
References	1. Toyota T, et, al. Inhibitory action of rat insulin and synthetic rat C-peptide on insulin secretion in the perfused rat pancreas. Acta Diabetol Lat. Sep-Dec 1977; 14(5-6): 250-6. 2. Wójcikowski C, et, al. Effects of synthetic rat C-peptide in normal and diabetic rats. Diabetologia. 1983 Sep;25(3):288-90.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

